A Randomized, Double-blind, Multicenter Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of Sub-cutaneous Secukinumab in Subjects of Body Weight 90 kg or Higher With Moderate to Severe Chronic Plaque-type Psoriasis
Phase of Trial: Phase III
Latest Information Update: 15 Jun 2019
Price : $35 *
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 22 May 2019 Planned End Date changed from 25 Mar 2021 to 21 Aug 2020.
- 22 May 2019 Planned primary completion date changed from 25 Mar 2021 to 24 Feb 2020.
- 11 Jul 2018 Status changed from not yet recruiting to recruiting.